MA47206A - Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 - Google Patents
Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3Info
- Publication number
- MA47206A MA47206A MA047206A MA47206A MA47206A MA 47206 A MA47206 A MA 47206A MA 047206 A MA047206 A MA 047206A MA 47206 A MA47206 A MA 47206A MA 47206 A MA47206 A MA 47206A
- Authority
- MA
- Morocco
- Prior art keywords
- tim
- antibodies
- cancer treatment
- treatment methods
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444354P | 2017-01-09 | 2017-01-09 | |
| US201762582272P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47206A true MA47206A (fr) | 2019-11-13 |
Family
ID=61163782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047206A MA47206A (fr) | 2017-01-09 | 2018-01-09 | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11926665B2 (fr) |
| EP (1) | EP3565594A1 (fr) |
| JP (2) | JP7118073B2 (fr) |
| KR (1) | KR102671283B1 (fr) |
| CN (1) | CN110382000A (fr) |
| AU (1) | AU2018205401B2 (fr) |
| BR (1) | BR112019014169A2 (fr) |
| CA (1) | CA3049536A1 (fr) |
| IL (1) | IL267803A (fr) |
| MA (1) | MA47206A (fr) |
| MX (1) | MX2019008208A (fr) |
| SG (1) | SG10201913083SA (fr) |
| TW (2) | TWI793094B (fr) |
| WO (1) | WO2018129553A1 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| SMT202400420T1 (it) * | 2015-04-01 | 2024-11-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina dell’immunoglobulina delle cellule t e della mucina 3 (tim-3) |
| TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| MA46724A (fr) | 2016-11-01 | 2021-04-21 | Anaptysbio Inc | Anticorps dirigés contre la mort programmée 1 (pd -1) |
| KR20190098741A (ko) | 2016-11-01 | 2019-08-22 | 아납티스바이오, 아이엔씨. | T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체 |
| MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| MA47208A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 |
| CN110831580A (zh) * | 2017-05-09 | 2020-02-21 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| JP7269227B2 (ja) | 2017-09-26 | 2023-05-08 | テサロ， インコーポレイテッド | ニラパリブ処方物 |
| CA3076515A1 (fr) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Polytherapies pour le traitement du cancer |
| CN111182923A (zh) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | 组合疗法及其用途 |
| US20210363242A1 (en) * | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| CN118994103A (zh) | 2018-10-03 | 2024-11-22 | 特沙诺有限公司 | 尼拉帕利盐 |
| CN113330007A (zh) | 2018-10-03 | 2021-08-31 | 特沙诺有限公司 | 尼拉帕利游离碱的晶体形式 |
| AU2019371457A1 (en) * | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Anti-TIM-3 antibodies |
| BR112021007968A2 (pt) | 2018-12-19 | 2021-09-08 | Bayer Aktiengesellschaft | Combinação farmacêutica de anticorpos anti-ceacam6 e tim3 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| EA202191526A1 (ru) * | 2019-01-11 | 2021-10-05 | Эли Лилли Энд Компани | Антитела к tim-3 и комбинации с другими ингибиторами контрольных точек для лечения злокачественного новообразования |
| WO2020165374A1 (fr) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Molécule bifonctionnelle comprenant il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| JP2023521227A (ja) | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| EP4136113A1 (fr) | 2020-04-14 | 2023-02-22 | GlaxoSmithKline Intellectual Property Development Limited | Traitement combiné pour le cancer impliquant des anticorps anti-icos et anti-pd1, impliquant éventuellement en outre des anticorps anti-tim3 |
| WO2022006091A1 (fr) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Formulation biopharmaceutique d'anticorps monoclonaux thérapeutiques anti-pd-1, anti-pd-l1, et anti-vegfr et procédé de traitement de nsclc par inhalation |
| WO2022148781A1 (fr) | 2021-01-05 | 2022-07-14 | Institut Curie | Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4320155A1 (fr) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées |
| KR20230171452A (ko) * | 2021-04-13 | 2023-12-20 | 메디뮨 엘엘씨 | Pd-1 및 tim-3을 표적으로 하는 이중특이적 항체 |
| EP4326773A4 (fr) | 2021-04-23 | 2025-09-24 | Suzhou Neologics Bioscience Co Ltd | Anticorps ciblant tim-3 et leurs utilisations |
| US11970548B2 (en) * | 2021-08-27 | 2024-04-30 | Innovative Cellular Therapeutics Holdings, Ltd. | Nanobody target GCC and uses in chimeric antigen receptor cell therapy |
| EP4396229A1 (fr) | 2021-09-02 | 2024-07-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anticorps anti-cecam6 à effets secondaires réduits |
| WO2024003360A1 (fr) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarqueurs et leurs utilisations pour le traitement du neuroblastome |
| WO2024028386A1 (fr) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Molécule multifonctionnelle dirigée contre cd28 |
| TW202440634A (zh) * | 2023-03-08 | 2024-10-16 | 美商英塞特公司 | 用於治療癌症之抗－ｐｄ－１活性劑、抗－ｔｉｍ－３活性劑及抗－ｌａｇ－３活性劑之組合療法 |
| WO2024200826A1 (fr) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Nanoparticule à base de lipides ciblée au niveau de cellules immunitaires activées pour l'expression d'une molécule inhibitrice de cellules immunitaires et son utilisation |
| EP4687991A1 (fr) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation |
| WO2025014933A1 (fr) * | 2023-07-10 | 2025-01-16 | Northwestern University | Ciblage de tim-3 dans un gliome induit par mapk |
| WO2025242835A1 (fr) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement du cancer |
| WO2025242836A1 (fr) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement de maladies et de troubles auto-immuns ou inflammatoires |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1992008796A1 (fr) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Genes de fusion selectionnables bifonctionnels |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US6843987B2 (en) | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| CA2467633C (fr) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Categorisation d'anticorps reposant sur des caracteristiques de liaison |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| WO2003089609A2 (fr) | 2002-04-17 | 2003-10-30 | Richard Metz | Substitution homologue de fragments courts d'adn permettant d'obtenir des bovins resistants a l'esb |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| US7824681B2 (en) | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
| AR062065A1 (es) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
| TR201802814T4 (tr) | 2006-07-14 | 2018-03-21 | Ac Immune Sa | Amiloid betaya karşı insanlaştırılmış antikor. |
| JP5577543B2 (ja) | 2006-09-08 | 2014-08-27 | アムジエン・インコーポレーテツド | Ｉｌ−１ファミリーバリアント |
| EP2109608B1 (fr) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp) |
| EP2126105A4 (fr) | 2007-02-20 | 2010-11-03 | Anaptysbio Inc | Systèmes d'hypermutation somatique |
| CA2691357C (fr) | 2007-06-18 | 2014-09-23 | N.V. Organon | Anticorps diriges contre le recepteur humain de mort programmee pd-1 |
| WO2009087381A1 (fr) | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Ltd | Sels pharmaceutiquement acceptables de 2-{4-[(35)-pipéridin-3-yl]phényl)-2h-indazole-7-carboxamide |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2009129247A2 (fr) | 2008-04-14 | 2009-10-22 | Innovative Targeting Solutions Inc. | Creation de diversite de sequences dans des immunoglobulines |
| JP2012501184A (ja) | 2008-08-28 | 2012-01-19 | ワイス・エルエルシー | 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用 |
| JP6158511B2 (ja) | 2010-06-11 | 2017-07-05 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体 |
| CA2802344C (fr) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques |
| WO2013006490A2 (fr) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Anticorps se liant spécifiquement à tim3 |
| WO2013016220A1 (fr) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Récepteur a de il-il-17 requis pour biologie il-17c |
| EP2748197A2 (fr) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Anticorps bispécifiques à fc en tandem |
| WO2013074569A1 (fr) | 2011-11-16 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Anticorps anti-il-36r |
| EP2797952B1 (fr) | 2011-12-28 | 2019-02-27 | ImmunoQure AG | Procédé de fourniture d'auto-anticorps monoclonaux avec une spécificité désirée |
| KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| CA2905940A1 (fr) | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Anticorps humanises anti-n2 |
| WO2014140240A1 (fr) | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Anticorps aptes à lier spécifiquement deux épitopes sur un inhibiteur de la voie d'un facteur tissulaire |
| HUE053069T2 (hu) | 2013-05-02 | 2021-06-28 | Anaptysbio Inc | Programozott halál-1 (PD-1) ellen irányuló ellenanyagok |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| CA2964830C (fr) | 2014-11-06 | 2024-01-02 | F. Hoffmann-La Roche Ag | Anticorps anti-tim3 et procedes d'utilisation |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| SMT202400420T1 (it) | 2015-04-01 | 2024-11-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina dell’immunoglobulina delle cellule t e della mucina 3 (tim-3) |
| EP3964528A1 (fr) | 2015-07-29 | 2022-03-09 | Novartis AG | Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3 |
| LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| CA3029671C (fr) | 2016-06-29 | 2023-08-15 | Tesaro, Inc. | Methodes de traitement du cancer de l'ovaire |
| CN116478290A (zh) | 2016-08-26 | 2023-07-25 | 百济神州有限公司 | 抗tim-3抗体及其用途 |
| KR20190098741A (ko) | 2016-11-01 | 2019-08-22 | 아납티스바이오, 아이엔씨. | T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체 |
| MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2018
- 2018-01-09 MA MA047206A patent/MA47206A/fr unknown
- 2018-01-09 JP JP2019537099A patent/JP7118073B2/ja active Active
- 2018-01-09 WO PCT/US2018/013021 patent/WO2018129553A1/fr not_active Ceased
- 2018-01-09 KR KR1020197023158A patent/KR102671283B1/ko active Active
- 2018-01-09 TW TW107100821A patent/TWI793094B/zh active
- 2018-01-09 SG SG10201913083SA patent/SG10201913083SA/en unknown
- 2018-01-09 US US16/476,534 patent/US11926665B2/en active Active
- 2018-01-09 TW TW112102836A patent/TWI841209B/zh active
- 2018-01-09 MX MX2019008208A patent/MX2019008208A/es unknown
- 2018-01-09 AU AU2018205401A patent/AU2018205401B2/en active Active
- 2018-01-09 EP EP18703388.1A patent/EP3565594A1/fr active Pending
- 2018-01-09 CN CN201880016126.4A patent/CN110382000A/zh active Pending
- 2018-01-09 BR BR112019014169-3A patent/BR112019014169A2/pt unknown
- 2018-01-09 CA CA3049536A patent/CA3049536A1/fr active Pending
-
2019
- 2019-07-02 IL IL267803A patent/IL267803A/en unknown
-
2022
- 2022-04-05 JP JP2022062862A patent/JP7472190B2/ja active Active
-
2024
- 2024-02-02 US US18/430,835 patent/US20240301057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019014169A2 (pt) | 2020-02-11 |
| JP2020503364A (ja) | 2020-01-30 |
| US11926665B2 (en) | 2024-03-12 |
| AU2018205401A1 (en) | 2019-07-25 |
| EP3565594A1 (fr) | 2019-11-13 |
| TWI793094B (zh) | 2023-02-21 |
| TWI841209B (zh) | 2024-05-01 |
| JP7472190B2 (ja) | 2024-04-22 |
| US20190322746A1 (en) | 2019-10-24 |
| TW202319068A (zh) | 2023-05-16 |
| TW201831196A (zh) | 2018-09-01 |
| SG10201913083SA (en) | 2020-03-30 |
| KR20190098263A (ko) | 2019-08-21 |
| WO2018129553A1 (fr) | 2018-07-12 |
| KR102671283B1 (ko) | 2024-06-03 |
| CA3049536A1 (fr) | 2018-07-12 |
| IL267803A (en) | 2019-09-26 |
| JP2022087185A (ja) | 2022-06-09 |
| CN110382000A (zh) | 2019-10-25 |
| JP7118073B2 (ja) | 2022-08-15 |
| US20240301057A1 (en) | 2024-09-12 |
| MX2019008208A (es) | 2019-12-11 |
| AU2018205401B2 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47206A (fr) | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
| EP3723803A4 (fr) | Anticorps anti-trem2 et méthodes associées | |
| EP3752180A4 (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| EP3581651A4 (fr) | Anticorps anti-gprc5d et molécule le contenant | |
| EP3658589C0 (fr) | Anticorps anti-sirp-alpha et méthodes associées | |
| EP3454945A4 (fr) | Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| EP3641752A4 (fr) | Méthodes de traitement du cancer au moyen de compositions comprenant de l'amlexanox et des immunomodulateurs | |
| MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
| MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
| MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP3606544A4 (fr) | Thérapie au moyen de mini-gènes | |
| EP3606531A4 (fr) | Méthodes de traitement du cancer | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| EP3773633A4 (fr) | Méthodes de traitement de glioblastomes | |
| EP3681498A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| EP3344767A4 (fr) | Sélection de la taille d'acides nucléiques au moyen de petites molécules | |
| EP3373937A4 (fr) | Conjugués anticorps anti-her22-maytansine et méthodes d'utilisation de ceux-ci | |
| EP3638293A4 (fr) | Méthodes et compositions pour le traitement du cancer |